Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Chamberland (NPI 1447293311)

Field	Value
Entity Type	Individual
Organization	David Chamberland
Address	1365 Poplar Dr
City	Medford
State	OR
ZIP	97504
Taxonomy	Rheumatology Physician
NPI Enumerated	June 14, 2006

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

DAVID CHAMBERLAND is a Rheumatology Physician in MEDFORD, OR with an NPI enumerated on 2006-06-14 (~20 years ago). His lifetime Medicare revenue is $2.8M and there is no Medicaid billing on file, making his Medicare business the dominant (effectively sole) payer relationship reflected in the dataset. This tenure and payer concentration suggest an established practice with a Medicare-skewed patient base.

Revenue concentration is high: the precomputed top three Medicare codes account for 62.8% of this provider's total Medicare revenue, driven by J0129, J3262, and J1602. Those three codes (J0129 at $974.3K / 33.9%, J3262 at $495.1K / 17.2%, and J1602 at $333.9K / 11.6%) together form the bulk of billings, indicating revenue is heavily dependent on a small number of biologic drug administrations.

The code mix points to a specialist practice built around in-office biologic and infusion therapy rather than procedural orthopedics or surgery: top revenue codes are J0129 (abatacept), J3262 (tocilizumab), and J1602 (golimumab), with additional notable use of J1745 (infliximab) and biosimilar Q5104. The presence of multiple high-revenue injectable biologics suggests the clinic provides on-site drug administration and management of chronic inflammatory conditions typical of rheumatology.

DAVID CHAMBERLAND ranks well above peers nationally on key biologic drugs: J0129 ranks #52 of 1221 providers (96th percentile; notably above typical national volume) and J3262 ranks #53 of 618 providers (92th percentile). J1602 ranks #154 of 1041 providers (85th percentile), a strong but less dominant position. These rank/percentile patterns characterize the provider as a major national participant for abatacept and tocilizumab administration, and a significant regional player for golimumab.

Infusion and chemotherapy-administration activity is also elevated relative to peers: 96413 ($83K, 2.9% of Medicare revenue) ranks #160 of 7514 providers (98th percentile; notably above typical national volume) and 96415 ($8.6K, 0.3%) ranks #124 of 4959 providers (97th percentile). The combination of high-percentile chemotherapy/infusion administration codes alongside the biologic drug codes supports the conclusion that the practice operates substantial infusion capabilities and bills frequently for administration time.

Office evaluation-and-management activity is unusually high for an individual provider: 99214 accounts for $99K (3.4% of Medicare revenue) and ranks #7984 of 479517 providers (98th percentile; extreme outlier, far above typical national volume). This suggests substantial longitudinal management and follow-up of established patients in addition to infusion services, consistent with chronic disease management in rheumatology.

Supporting lab and diagnostic services appear as ancillary revenue streams rather than primary drivers: 80053 (CMP) at $9.8K ranks #1542 of 26416 providers (94th percentile) and 85025 (CBC) at $7.9K ranks #2411 of 32833 providers (93th percentile), while inflammatory marker testing (86140) and ESR (85651) also appear on the list. These lab code volumes indicate the practice performs on-site testing to support care, but these services represent a small share of total Medicare revenue.

From a payer-mix and business-risk perspective, the absence of any Medicaid billing on file (none below) makes this provider effectively single-payer (Medicare) in the reported dataset, concentrating reimbursement risk on Medicare policy and biologic drug payment. For payers or partners evaluating network capacity, the profile signals a mature, Medicare-focused infusion-oriented rheumatology practice with notable national standing on several biologic drug administrations but limited or no Medicaid participation in the available claims.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

52 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	29,530	$30	$974.3K
J3262	Injection, tocilizumab, 1 mg	99,020	$10	$495.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	30,350	$10	$333.9K
J9312	Injection, rituximab, 10 mg	3,970	$60	$250.1K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8,590	$30	$223.3K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	5,210	$30	$166.7K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	26,800	$1	$107.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,150	$90	$99K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	810	$100	$83K
J0897	Injection, denosumab, 1 mg	2,580	$20	$46.4K

Showing 1–10 of 52

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 52 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

David Chamberland — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

52 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	20	6,300	$30	$260.7K
J9312	3	10	3,750	$60	$220K
J3262	1	10	31,180	$1	$176.4K
J1602	2	20	13,600	$10	$156.4K
Q5104	2	10	3,850	$30	$129.7K
J0717	4	10	30,800	$1	$117.6K
J1745	3	20	3,750	$30	$115.2K
J0897	33	70	2,400	$20	$78.3K
96413	1	90	150	$100	$18.2K
86235	7	10	390	$20	$12.6K

Showing 1–10 of 52

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Chamberland, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rheumatology Clinic LLC	OR	Rheumatology Physician	$0	$3.9M
Dominik Sokalski	OR	Rheumatology Physician	$2.3M	$0
Giorgos Loizidis	PA	Rheumatology Physician	$31.8K	$0

Nearby Providers

Other providers in the same ZIP code as David Chamberland, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Asante	OR	General Acute Care Hospital	$0	$29.7M
Addictions Recovery Center, Inc.	OR	Substance Abuse Rehabilitation Facility	$0	$29.2M
Asante Physician Partners	OR	Family Medicine Physician	$0	$27.2M
Mercy Flights Incorporated	OR	Ambulance	$3.6M	$19.4M
Providence Health & Services - Oregon	OR	General Acute Care Hospital	$0	$20.9M
Crc Health Oregon, LLC	OR	Methadone Clinic	$193K	$13M
James Kolby Robinson, Dmd	OR	Pediatric Dentistry	$0	$11.6M
Valley Immediate Care, LLC	OR	Urgent Care Clinic/Center	$0	$9.4M
Lincare Inc	OR	Durable Medical Equipment & Medical Supplies	$0	$7.1M
Southern Oregon Pediatrics, LLP	OR	Pediatric Hospice and Palliative Medicine Physician	$0	$6.5M

David Chamberland — Billing Profile & Reimbursement Data

Sign up for David Chamberland — Billing Profile & Reimbursement Data policy alerts

David Chamberland — Billing Profile & Reimbursement Data

Sign up for David Chamberland — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References